RxDoctor Payments Data

Alex Childs, MD

Gynecology · Birmingham, ALNPI 1790749141

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,467 of the $9,088 with a category attached, or 60.2%. 50 manufacturers reported payments, led by AbbVie at 47.1% of the total. Reporting peaked in 2021 at $4,327 and has fallen 82.0% since, to $779 in 2025. Among gynecology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,088in general payments, 2019–2025

Across 327 payments — averaging $27.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Astellas Pharma US Inc$734
  • Sumitomo Pharma America, Inc.$522
  • Pfizer$320
  • Axonics, Inc.$250
  • Organon$221
  • plus $3K from 44 others

What the payments were for

  • Speaking & faculty fees$3,40037%
  • Food & beverage$5,46760%
  • Education$2212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,088 in reported general payments places this provider in the 95th percentile of 51 gynecology providers in Alabama.

See all gynecology providers in Alabama

Medicare billing

Part B allowed, 2024
$23,359
Medicare patients
106
Services billed
442

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron15$8,265
LinzessLinaclotide11$5,558
Pregabalin60$4,208
Gabapentin202$3,469
Estradiol117$3,170
Solifenacin Succinate46$2,727
Amitriptyline Hcl111$2,072
Estradiol (Twice Weekly)Estradiol16$1,587
Tizanidine Hcl102$1,045
Norethindrone Acetate26$947
Duloxetine Hcl35$825
Baclofen52$595
ValacyclovirValacyclovir Hcl23$581
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst34$563
Methocarbamol39$508

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$734$8,26515 claims
AbbVieLinzess$4,281$5,55811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 51 gynecology providers in Alabama.

Other gynecology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →